Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2531-2531